Epix diagnostic news

Epix retained JP Morgan Securities Inc. to explore strategic alternatives, including a sale of the biotech's assets, potential mergers, recapitalization or a strategic business combination. Epix also hired Canaccord Adams Inc. to seek financing. The company has restructured twice since October 2008. Epix's Vasovist gadofosveset trisodium received FDA approval in December as a diagnostic to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral artery disease. The biotech is seeking a partner to launch the product (see BioCentury, Oct. 27, 2008, & March 23, 2009). ...